Table 3.
Intragroups comparation of laboratory tests before (week 0) and after treatment (week 16)
| Parameters | Gliclazide | Vildagliptin | ||||
|---|---|---|---|---|---|---|
| Week 0 | Week 16 | P | Week 0 | Week 16 | P | |
| Insulin (pg/mL) | 716 ± 316.7 | 819.7 ± 391.9 | 0.160 | 705.59 ± 468.8 | 599.6 ± 417.7 | 0.021 |
| Glucagon (pg/mL) | 79.1 ± 43.1 | 77.7 ± 40.0 | 0.921 | 65.2 ± 36.1 | 46.6 ± 30.8 | 0.004 |
| A1c (%) | 9.2 ± 1.2 | 6.9 ± 1.1 | 0.000 | 8.7 ± 0.9 | 6.9 ± 0.9 | 0.000 |
| C-peptide (pg/mL) | 1882.0 ± 690.1 | 2092.8 ± 956.2 | 0.193 | 1627.2 ± 585.6 | 1622.6 ± 609.6 | 0.059 |
| GLP-1 pg/mL) | 38.3 ± 25.3 | 45.5 ± 21.1 | 0.218 | 44.7 ± 38.7 | 83.8 ± 74,5 | 0.026 |
| GIP (pg/mL) | 39.1 ± 15.2 | 45.6 ± 39.0 | 0.201 | 38.9 ± 25.7 | 44.7 ± 34.8 | 0.405 |
| TBAR (nmolMDA/mL) | 8.9 ± 1.4 | 8.47 ± 0.9 | 0.262 | 9.0 ± 1.6 | 8.0 ± 0.7 | 0.035 |
| TAOS | 215.9 ± 34.5 | 264.3 ± 34.0 | 0.179 | 257.5 ± 61.3 | 205.3 ± 28.2 | 0.417 |
Data are means ± SD. GLP-1, Glucagon like peptide 1; GIP Gastric inhibitory polypeptide, TBARS Thiobarbituric Acid reactive substances, TAOS antioxidant state